---
title: "Major Insider Buy Signals Growing Confidence at Treace Medical Concepts"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/288004252.md"
description: "Insider buying at Treace Medical Concepts (TMCI) by CEO John T. Treace, who purchased 115,520 shares for $339,704, indicates growing confidence in the company's prospects. Despite reaffirming 2026 revenue guidance, analysts remain neutral due to ongoing losses and negative cash flow. TMCI's stock has seen mixed fundamentals, with a current market cap of $183.6M and a year-to-date price performance of 18.37%. Technical signals suggest a sell, reflecting concerns over financial performance and a cautious outlook."
datetime: "2026-05-29T02:15:25.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/288004252.md)
  - [en](https://longbridge.com/en/news/288004252.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/288004252.md)
---

# Major Insider Buy Signals Growing Confidence at Treace Medical Concepts

New insider activity at Treace Medical Concepts ( (TMCI) ) has taken place on May 28, 2026.

### Memorial Day Sale – Claim 70% Off TipRanks

-   Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings and forecasts to breaking news and portfolio analysis.
-   Discover high-conviction stock picks and new investing opportunities with the TipRanks Smart Investor Newsletter

Treace Medical Concepts has seen a notable insider move as CEO John T. Treace purchased 115,520 shares of the company’s stock in a transaction valued at $339,704, signaling increased executive confidence in the business’s prospects.

**Recent Updates on TMCI stock**

Treace Medical Concepts’ stock action over the last day has been framed by mixed fundamentals and updated guidance rather than dramatic price swings. Analysts’ neutral stance stems from ongoing losses and negative free cash flow, which limit valuation support despite strong gross margins and some improvement in cash burn.

The company reaffirmed 2026 revenue and adjusted EBITDA guidance, emphasizing case volume growth but also warning of revenue headwinds from demand-driven product and price mix shifts. Investor sentiment was steadied by shareholder approval of the current board, executive compensation plan, and auditor, reinforcing confidence in the existing strategy and financial oversight while the market waits to see if execution can restore stronger growth in the back half of the year.

**Spark’s Take on TMCI Stock**

According to Spark, TipRanks’ AI Analyst, TMCI is a Neutral.

TMCI’s score is held back primarily by weak financial performance (persistent losses and negative free cash flow) and a cautious 2026 outlook (flat-to-declining revenue with continued adjusted EBITDA losses). Technicals are moderately supportive in the short term but show overbought signals and remain below the 200-day trend, while valuation is constrained by negative earnings and no dividend support.

To see Spark’s full report on TMCI stock, click here.

**More about Treace Medical Concepts**

**YTD Price Performance:** 18.37%

**Average Trading Volume:** 814,869

**Technical Sentiment Signal:** Sell

**Current Market Cap:** $183.6M

### Related Stocks

- [TMCI.US](https://longbridge.com/en/quote/TMCI.US.md)
- [XHE.US](https://longbridge.com/en/quote/XHE.US.md)
- [IHI.US](https://longbridge.com/en/quote/IHI.US.md)

## Related News & Research

- [Coram raised $35 million to turn security cameras into AI detectives](https://longbridge.com/en/news/289457582.md)
- [This Analyst Just Upgraded Chipotle Stock. Here's Why.](https://longbridge.com/en/news/289079873.md)
- [Top TJX Insider Makes Major Move With Multimillion-Dollar Stock Sale](https://longbridge.com/en/news/289406590.md)
- [Commvault Brings AI-Enabled Cyber Resilience to Pure Accelerate 2026 | CVLT Stock News](https://longbridge.com/en/news/289328291.md)
- [Why TJX Companies stock climbed while the market sputtered today](https://longbridge.com/en/news/289246675.md)